Insmed Incorporated
INSM · Nasdaq · United States
Share price · INSM
Loading chart…
Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento
Unusual price moves
Days when INSM's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked
- 29 Oct 2026+15.1%
- 6 Aug 2026+33.9%
- 5 Jun 2026-10.2%
Nothing announced by INSM that day or the session before.
- 12 May 2026+11.7%
Nothing announced by INSM that day or the session before.
- 7 May 2026-23.4%
Nothing announced by INSM that day or the session before.
- 24 Apr 2026-6.0%
Nothing announced by INSM that day or the session before.
- 23 Mar 2026+5.9%
Nothing announced by INSM that day or the session before.
- 19 Feb 2026+6.5%
Nothing announced by INSM that day or the session before.
- 21 Jan 2026-4.4%
Nothing announced by INSM that day or the session before.
- 18 Dec 2025-16.1%
Nothing announced by INSM that day or the session before.
Share of unusual movement by asset
For each asset, the share of INSM's own-move activity since 14 Oct 2025 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.
| Asset | Event days | Share of unusual movement |
|---|---|---|
| Other company news (earnings, financing, releases naming no asset) | — | 39% |
| Sessions with no dated event | — | 61% |
No dated announcements about its assets since 14 Oct 2025.
Assets
(1 total)
| Target & Modality | |||
|---|---|---|---|
| Phase 2 | Stem cell factor (SCF / KIT ligand)Monoclonal antibody | Atopic DermatitisAsthma |
Upcoming events
No upcoming trial completions or earnings dates on record for this company's assets.
Financial reports
Quarterly & interim (15)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q3 | $524M | $270M | $397M+ $750M short-term inv. | $100M-$36M operating cash flow | report ↗ |
View 14 more
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q2 | $425M | $210M | $545M+ $616M short-term inv. | $13M-$89M operating cash flow | report ↗ |
| 2026-Q1 | $306M | $209M | $582M+ $641M short-term inv. | $164M-$223M operating cash flow | report ↗ |
| 2025-Q3 | $142M | $186M | $335M+ $1.3B short-term inv. | $370M-$220M operating cash flow | report ↗ |
| 2025-Q2 | $107M | $177M | $1.3B+ $572M short-term inv. | $322M-$206M operating cash flow | report ↗ |
| 2025-Q1 | $93M | $153M | $403M+ $796M short-term inv. | $257M-$262M operating cash flow | report ↗ |
| 2024-Q3 | $93M | $151M | $461M+ $1.0B short-term inv. | $221M-$181M operating cash flow | report ↗ |
| 2024-Q2 | $90M | $147M | $1.2B+ $0 short-term inv. | $301M-$123M operating cash flow | report ↗ |
| 2024-Q1 | $76M | $121M | $596M+ $0 short-term inv. | $157M-$184M operating cash flow | report ↗ |
| 2023-Q3 | $79M | $109M | $487M+ $299M short-term inv. | $159M-$136M operating cash flow | report ↗ |
| 2023-Q2 | $77M | $197M | $613M+ $305M short-term inv. | $245M-$123M operating cash flow | report ↗ |
| 2023-Q1 | $65M | $128M | $969M+ $30M short-term inv. | $160M-$146M operating cash flow | report ↗ |
| 2022-Q3 | $68M | $100M | $415M+ $99M short-term inv. | $131M-$90M operating cash flow | report ↗ |
| 2022-Q2 | $65M | $89M | $416M+ $139M short-term inv. | $96M-$102M operating cash flow | report ↗ |
| 2022-Q1 | $53M | $84M | $516M+ $119M short-term inv. | $95M-$105M operating cash flow | report ↗ |
Annual history (5 years)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2025-FY | $606M | $771M | $510M+ $920M short-term inv. | $319M-$935M operating cash flow | report ↗ |
View 4 more years
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2024-FY | $364M | $598M | $555M+ $879M short-term inv. | $228M-$684M operating cash flow | report ↗ |
| 2023-FY | $305M | $571M | $482M+ $298M short-term inv. | $187M-$536M operating cash flow | report ↗ |
| 2022-FY | $245M | $398M | $1.1B+ $74M short-term inv. | $120M-$400M operating cash flow | report ↗ |
| 2021-FY | $188M | $273M | $717M+ $0 short-term inv. | $109M-$363M operating cash flow | report ↗ |
Insider transactions
Open-market activity, trailing 12 months: 0 purchases ($0), 147 sales ($133.7M). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.
| Source | ||||||
|---|---|---|---|---|---|---|
| 2026-10-19 | Koppikar Utpal · director | Award / grant | 6,139 | — | — | Form 4 |
| 2026-10-19 | Hudson Paul · director | Award / grant | 6,139 | — | — | Form 4 |
| 2026-09-09 | Brennan David R · director | Open-market sale | 25,000 | $124.00 | $3.1M | Form 4 |
| 2026-08-17 | SHAROKY MELVIN MD · director | Open-market sale | 5,000 | $127.53 | $638K | Form 4 |
| 2026-08-10 | Adsett Roger · Chief Operating Officer | Option exercise | 82,280 | $13.67 | $1.1M | Form 4 |
| 2026-08-10 | Adsett Roger · Chief Operating Officer | Option exercise | 76,600 | $17.16 | $1.3M | Form 4 |
| 2026-08-10 | Adsett Roger · Chief Operating Officer | Option exercise | 80,970 | $30.46 | $2.5M | Form 4 |
| 2026-08-10 | Adsett Roger · Chief Operating Officer | Open-market sale | 239,850 | $133.27 | $32.0M | Form 4 |